| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | CLOVIS ONCOLOGY INC | 407,416 | 35,803,718 | 45.41% | ||
| 2 | FIVE PRIME THERAPEUTICS INC | 1,092,152 | 27,129,055 | 34.41% | ||
| 3 | ACHAOGEN INC COM | 1,281,152 | 7,725,346 | 9.80% | ||
| 4 | Biotie Therapies Corp. | 268,672 | 5,365,379 | 6.81% | ||
| 5 | CymaBay Therapeutics | 1,048,601 | 2,820,736 | 3.58% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001104659-15-051249, filed 2015.07.15).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
